Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

BACKGROUND: Redirection of T lymphocytes against tumor antigens can induce dramatic regression of advanced stage malignancy. The use of bispecific antibodies (BsAbs) that bind both the T-cell receptor (TCR) and a target antigen is one promising approach to T-cell redirection. However, BsAbs indiscri...

Descripción completa

Detalles Bibliográficos
Autores principales: Urbanska, Katarzyna, Lynn, Rachel C, Stashwick, Caitlin, Thakur, Archana, Lum, Lawrence G, Powell, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272781/
https://www.ncbi.nlm.nih.gov/pubmed/25496493
http://dx.doi.org/10.1186/s12967-014-0347-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272781/
https://www.ncbi.nlm.nih.gov/pubmed/25496493
http://dx.doi.org/10.1186/s12967-014-0347-2

Ejemplares similares